文献速递临床试验与 GCP

阿育吠陀干预与瑜伽对COVID-19长期效应的安全性和有效性:随机对照试验研究方案的结构化摘要

Safety and efficacy of Ayurvedic interventions and Yoga on long term effects of COVID-19: A structured summary of a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-06-03

本研究为多中心、随机、对照、平行组、开放标签的探索性试验,旨在评估阿育吠陀干预与瑜伽对比WHO康复自我管理对COVID-19长期效应患者的康复疗效与安全性。主要结局为呼吸功能变化,计划每组约55例、共110例受试者,干预90天。

要点

  • 阿育吠陀干预包括Agastya Haritaki 6克与Ashwagandha片500毫克每日两次,联合每日瑜伽。
  • 对照为WHO Rehabilitation Self-Management after COVID-19相关疾病,干预90天。
  • 主要结局为呼吸功能,采用圣迭戈呼吸困难问卷、6分钟步行试验和肺功能测试评估。

核心结论

  • 该研究方案旨在评估阿育吠陀干预与瑜伽对COVID-19长期效应患者康复的有效性和安全性。

研究设计与样本

  • 多中心、随机、对照、平行组、开放标签、探索性研究,在印度马哈拉施特拉邦的两所医学院开展。
  • 计划每组约55例,共110例受试者,按1:1随机分组,研究总时长9个月,干预期90天。

关键数值与推荐

  • 纳入18至60岁、男女不限、可走动、愿意参与、有不超过4周的COVID-19 RT-PCR阳性或IgM抗体阳性史、筛查时RT-PCR阴性者。
  • 排除危重症ARDS需ICU有创呼吸支持、恶性肿瘤、免疫抑制状态(如HIV)、糖尿病、活动性肺结核、慢性呼吸疾病史、运动神经元病、多发性硬化、卒中、认知障碍、房颤、急性冠脉综合征、心梗、严重心律失常、严重肝病或肾病、妊娠或哺乳期、使用免疫抑制剂、对试验药物过敏、抑郁病史、精神病诊断、物质依赖或酗酒者。
  • 干预组:Agastya Haritaki 6克和Ashwagandha片500毫克每日两次口服(饭后温水送服),每日两次瑜伽(早晨30分钟、傍晚15分钟),共90天。
  • 对照组:WHO Rehabilitation Self-Management after COVID-19相关疾病,共90天。
  • 主要结局:圣迭戈呼吸困难问卷、6分钟步行试验和肺功能测试评估的呼吸功能变化。

临床怎么用

  • 该方案为COVID-19长期效应患者提供了一种基于阿育吠陀和瑜伽的康复干预选项,其疗效和安全性有待试验结果验证。

局限性

  • 开放标签设计可能引入实施偏倚,尽管结局评估者设盲。
  • 样本量基于6分钟步行试验的假设效应量,可能影响对其他结局的检验效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Primary Objective • To assess the efficacy of Ayurveda interventions and Yoga in rehabilitation of COVID-19 cases suffering with long term effects of COVID 19 as compared to WHO Rehabilitation Self-Management after COVID-19- Related Illness. Secondary Objective • To assess the safety of Ayurvedic interventions in cases suffering with long term effects of COVID 19 TRIAL DESIGN: Multi-centric, randomized, controlled, parallel group, open-label, exploratory study. The study duration is 9 months and the intervention period is 90 days from the day of enrolment of the participant. PARTICIPANTS: Patients of either sex between 18 to 60 years, ambulatory, willing to participate, with history (not more than 4 weeks) of positive RT-PCR for COVID-19 or IgM antibodies positivity for SARS CoV-2, but having negative RT-PCR for COVID-19 at the time of screening will be considered eligible for enrolment in the study. Critically ill patients with ARDS (acute respiratory distress syndrome), requiring invasive respiratory support in the intensive care unit, known case of any malignancy, immune-compromised state (e.g. HIV), diabetes mellitus, active pulmonary tuberculosis, past history of any chronic respiratory disease, motor neuron disease, multiple sclerosis, stroke, impaired cognition, atrial fibrillation, acute coronary syndrome, myocardial infarction, severe arrhythmia, concurrent serious hepatic disease or renal disease, pregnant or lactating women, patients on immunosuppressive medications, history of hypersensitivity to the trial drugs or their ingredients, depressive illness (before COVID-19), diagnosed psychotic illnesses, substance dependence or alcoholism will be excluded. The trial will be conducted at two medical colleges in Maharashtra, India. INTERVENTION AND COMPARATOR: Intervention Arm (Group-I): Ayurveda interventions including Agastya Haritaki six gram and Ashwagandha tablet 500 mg twice daily orally after meals with warm water and two sessions of yoga (morning 30 minutes and evening 15 minutes) daily for 90 days, as per the post-COVID-19 care protocol provided in National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19 published by Ministry of AYUSH, Government of India. Comparator Arm (Group-II): WHO Rehabilitation Self-Management after COVID-19 related illness for 90 days. The trial drugs are being procured from a GMP certified pharmaceutical company. MAIN OUTCOMES: Primary Outcome: Change in respiratory function to be assessed by San Diego shortness of breath Questionnaire, 6-minutes walk test and pulmonary function test. SECONDARY OUTCOMES: Change in High-resolution Computed Tomography (HRCT) Chest Change in Fatigue score assessed by Modified Fatigue Impact Scale Change in Anxiety score assessed by Hospital Anxiety and Depression Scale Score Change in Sleep Quality assessed by Pittsburgh Sleep Quality Index Change in the quality of life assessed by COV19-QoL scale Safety of the interventions will be assessed by comparing hematological and biochemical investigations before and after the intervention period and Adverse Event/ Adverse drug reaction TIMELINES FOR OUTCOME ASSESSMENT: Subjective parameters and clinical assessment will be assessed at baseline, 15th day, 30th day, 60th day and 90th day. Laboratory parameters (CBC, LFT, KFT, HbA1c, Hs-CRP, D-dimer), Pulmonary function test and HRCT Chest will be done at baseline and after completion of study period i.e. 90th day. RANDOMISATION: Statistical package for Social Sciences (SPSS) version 15.0 is used to generate the random number sequences. The participants will be randomized to two study groups in the ratio of 1:1. BLINDING (MASKING): The study is open-label design. However, the outcome assessor will be kept blinded regarding the study group allocation of the participants. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) SAMPLE SIZE: The sample size for the study is calculated assuming improvement in 6-minutes walk test by 40 meter in Group I and a change of 10 meter in Group II with a standard deviation of 50 meter based on the results of the previous studies, with 95% Confidence Level (α = 0.05) and 80% power and expecting a dropout rate of 20%. The number of participants to be enrolled in the study should be approximately 55 in each group. Hence, a total of 110 participants will be enrolled in the trial at each study site. TRIAL STATUS: Participants' recruitment started on 1st May 2021. Anticipated end of recruitment is August 2021. Protocol number: CCRAS-01 Protocol version number: 1.1, 13th January 2021. TRIAL REGISTRATION: The trial is prospectively registered with the Clinical Trial Registry of India (CTRI) on 03rd March 2021 [ CTRI/2021/03/031686 ]. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Journal website (Additional file 1). This communication serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yadav B, Rai A, Mundada PS, et al. Safety and efficacy of Ayurvedic interventions and Yoga on long term effects of COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021. PMID: 34082792. doi:10.1186/s13063-021-05326-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。